A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...

The FDA has expanded the approval of Emend's indication for chemotherapy-induced nausea and vomiting. The FDA has approved Emend (aprepitant capsules) in combination with other antiemetic agents for ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...

Aprepitant 125mg; per pouch; pwd for oral susp after reconstitution. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors with little or no affinity for ...

Merck & Co has been given the go ahead in the USA to market its Emend drug to treat nausea and vomiting in patients who undergo surgery, increasing the number of patients eligible to receive treatment ...

EMEND (aprepitant) TriPack: 80mg + 125mg capsules The Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Emend (aprepitant; Merck) to include patients 12-17 ...

Merck & Co’s nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. The 1,000-patient trial ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Oral Emend improved gastroparesis symptoms based on commonly used gastroparesis measures in a ...

Merck’s drug for chemo-induced nausea and vomiting has some new competition. On Thursday, the FDA approved Cinvanti from California’s Heron Therapeutics, and it’ll go up against the New Jersey pharma ...